Clinical Study

Analgesic Effects of Intra-Articular Bupivacaine/Intravenous Parecoxib Combination Therapy versus Intravenous Parecoxib Monotherapy in Patients Receiving Total Knee Arthroplasty: A Randomized, Double-Blind Trial

Shih-Jyun Shen,¹,² Pei-Yu Peng,³ Hsiu-Pin Chen,¹,² Jr-Rung Lin,⁴ Mel S. Lee,¹,⁵ and Huang-Ping Yu¹,²

¹Department of Anesthesiology, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan
²College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
³Department of Nursing, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan
⁴Clinical Informatics and Medical Statistics Research Center, Chang Gung University, Taoyuan 333, Taiwan
⁵Department of Orthopaedic Surgery, Chang Gung Memorial Hospital, Chiayi 613, Taiwan

Correspondence should be addressed to Huang-Ping Yu; yuhp2001@adm.cgmh.org.tw

Received 14 May 2015; Accepted 2 June 2015

Academic Editor: Sebastian Straube

Copyright © 2015 Shih-Jyun Shen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objectives. The purpose of this double-blind, randomized study was to investigate whether the addition of intra-articular bupivacaine to intravenous parecoxib could improve pain relief in patients undergoing total knee arthroplasty. Methods. A total of 36 patients undergoing total knee arthroplasty were enrolled into our study. These patients were randomly allocated either to a placebo-controlled group or study group. Postoperative pain scores and analgesic consumption were evaluated. Results. Numeric rating scale (NRS) data of bupivacaine group in postoperative room were significantly lower than that of control group (control group versus bupivacaine group, 7.9 (6.7–9.1) (mean and 95% confidence interval) versus 4.5 (3.2–5.8) (mean and 95% confidence interval), \( p = 0.001 \)). NRS data of bupivacaine group in ward were also significantly lower than that of control group. A significantly lower dose of meperidine was used in the study group postoperatively during the first 24 hours (control group versus bupivacaine group, 3.08 ± 0.80 mg/Kg versus 2.34 ± 0.42 mg/Kg, \( p = 0.001 \)). Conclusion. Intra-articular bupivacaine in combination with intravenous parecoxib may improve pain relief and reduce the demand for rescue analgesics in patients undergoing total knee arthroplasty. The trial is registered with Australian New Zealand Clinical Trials Registry (ACTRN12615000463572).

1. Introduction

Knee surgeries usually lead to severe postoperative pain [1], which may result in poor joint motion, leading to extended hospitalization days and delayed rehabilitation [2]. Many methods such as drugs, nerve block, and epidural analgesia [2, 3] have been discussed for pain relief.

Among these, nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used for pain relief [4, 5]. Parecoxib, a cyclooxygenase-2 selective inhibitor, is widely used for postoperative pain relief [6]. However, previous studies have shown that the analgesic effect of parecoxib alone is not adequate in patients undergoing knee surgery [7].

Intra-articular drug injections may reduce pain following joint operation [8]. Furthermore, intra-articular morphine administered can provide pain relief after anterior cruciate ligament reconstruction [9]. Recent studies have shown that intra-articular bupivacaine injection has an analgesic effect after total hip replacement and a good opioid-sparing effect in the first 12 hours following hip surgery [10]. Local anesthetic is injected into the intra-articular cavity after surgical wound closure, spreading into muscle and soft tissue, which can...
effectively decrease postoperative pain. In view of this, we hypothesized that intra-articular bupivacaine in combination with intravenous parecoxib may improve postoperative pain relief in patients undergoing total knee arthroplasty.

2. Material and Methods

2.1. Patient Selection. The study was approved by the Institutional Review Board of Chang Gung Medical Foundation prior to the start of the trial. Written informed consent was obtained from every participant. A total of 40 patients (of both sexes) were prospectively included in the study. All patients were scheduled for total knee arthroplasty under general anesthesia between December 2012 and March 2013. The inclusion criterion was patients with knee osteoarthritis who were recommended for total knee arthroplasty. Preoperative evaluation for general anesthesia was performed. Exclusion criteria included neuropathic pain or sensory disorder in the knee requiring surgery, coagulation abnormalities, severe renal or hepatic impairment, and chronic opioid use. The neuropathic pain was detected according to the modified painDETECT questionnaire [11].

2.2. Study Setting. All participants were randomly assigned to either the control group (preoperative intravenous parecoxib) or the bupivacaine group (intra-articular bupivacaine combined with preoperative intravenous parecoxib) on the basis of a concealed allocation approach. A computerized random number table with no restrictions on the randomization was used to determine this allocation. Numbered, opaque, sealed envelopes containing the randomization schedule were kept by an investigator who was not an assessor of the study. The envelopes were opened immediately before the intra-articular injection. All patients were blinded to their allocation. Parecoxib 40mg was injected intravenously 1 hour before operation. All enrolled patients received general anesthesia by means of orotracheal intubation with propofol (2 mg/Kg), fentanyl (2 mcg/Kg), and cisatracurium (0.2 mg/Kg). Anesthesia was maintained with sevoflurane. In all cases, fentanyl was not given during the last 30 minutes of surgery. Surgery procedures were performed by the same orthopedic technique. After the closure of the surgical wound, an intra-articular injection of 0.5% bupivacaine 60 mL (300 mg) or 0.9% normal saline 60 mL was given into the joint space. The bupivacaine and normal saline were prepared by the pharmacy and were exteriorly indistinguishable. Hence, both the patients receiving the intra-articular injection and the doctor attending these patients did not know which drug was injected.

2.3. Postoperative Pain Assessment and Analgesic Protocol. After operation, the numeric rating scale (NRS) scores, wherein score 0 denoted no pain and score 10 denoted the worst pain, were used for the first time for pain assessment. If the NRS score exceeded 4, an intramuscular meperidine 50 mg injection was given for pain relief. The frequency of assessment was every 4 hours and an intramuscular meperidine 50 mg injection was given if needed. Data were collected by nursing staff who were unaware of the study.

2.4. Outcome Measurement. The primary outcome was the NRS scores after the operation. The secondary outcome was the amount of meperidine use within the first 24 hours after the operation.

2.5. Statistical Analysis. Data were collected and expressed as number, percentage, and mean ± standard deviation. The statistical result of pain scores was expressed as mean and 95% confidence interval. Unpaired Student’s t-test was used for analysis. A p value < 0.05 was considered to be statistically significant. All statistical data were analyzed using the SPSS statistical software.

3. Results

3.1. Patient Characteristics. Forty patients were enrolled in this study. Four of them were excluded. Two patients declined to participate. One patient had a sensory disorder in the knee and required surgery and one patient had severe renal impairment. The CONSORT flow diagram for the study is shown in Figure 1.

The basic data and preoperative comorbidities of all the patients are shown in Table 1. These patients were similar in age, gender, and American Society of Anesthesiologists (ASA) physical status distribution.

3.2. Postoperative Pain Assessment. NRS scores obtained in the postoperative room and in the ward, 24 hours following the operation, are expressed in Tables 2 and 3. NRS data of the bupivacaine group in the postoperative room were significantly lower than those of the control group (control group versus bupivacaine group, 7.9 (6.7, 9.1) versus 4.5 (3.2, 5.8), p = 0.001). NRS data of bupivacaine group in the ward were also significantly lower than those of control group (control group versus bupivacaine group, 7.6 (6.4, 8.7) versus 4.5 (3.6, 5.3), p = 0.0002).

Figure 2 shows the postoperative NRS scores. NRS scores of bupivacaine group were significantly lower than those of control group on the first day following the operation.

3.3. Postoperative Analgesic Consumption. The total amount of meperidine use is shown in Table 4 (control group versus bupivacaine group, 3.08 ± 0.80 mg/Kg versus 2.34 ± 0.42 mg/Kg, p = 0.001), indicating that patients under intra-articular bupivacaine intervention had a lower amount of meperidine use within 24 hours following the operation.

4. Discussion

The results of this prospective study suggested that intra-articular bupivacaine (300 mg) in combination with intravenous parecoxib (40 mg) could improve pain relief and reduce meperidine requirements in the management of postoperative pain during the first 24 hours following total knee arthroplasty. Poor control of postoperative pain may lead
Table 1: General characteristics of patients enrolled.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Control group (n = 16)</th>
<th>Bupivacaine group (n = 20)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (year)</td>
<td>51.2 ± 13.5</td>
<td>53.1 ± 14.8</td>
<td>0.581</td>
</tr>
<tr>
<td>Male gender</td>
<td>9 (56%)</td>
<td>11 (55%)</td>
<td>0.940</td>
</tr>
<tr>
<td>ASA status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>6 (38%)</td>
<td>8 (40%)</td>
<td>0.878</td>
</tr>
<tr>
<td>III</td>
<td>10 (63%)</td>
<td>12 (60%)</td>
<td></td>
</tr>
<tr>
<td>Preoperative comorbidities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>4 (25%)</td>
<td>6 (30%)</td>
<td>0.519</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>4 (25%)</td>
<td>7 (35%)</td>
<td>0.391</td>
</tr>
<tr>
<td>Asthma</td>
<td>1 (6%)</td>
<td>2 (10%)</td>
<td>0.585</td>
</tr>
<tr>
<td>Old cerebral embolism</td>
<td>1 (6%)</td>
<td>1 (5%)</td>
<td>0.698</td>
</tr>
<tr>
<td>Old myocardial infarction</td>
<td>1 (6%)</td>
<td>1 (5%)</td>
<td>0.698</td>
</tr>
</tbody>
</table>

Continuous variables were described as mean ± standard deviation, and the categorical variable was described as number of events (n/%); the remaining parameters were compared using an independent t-test, and statistical significance was considered when p < 0.05. Categorical variables were the number of events (n); the Chi-square test was used, and events less than 5 were compared with Fisher's exact test, p < 0.05.

40 patients who underwent total knee arthroplasty were assessed for eligibility (n = 40)

Exclusion criteria:
1. Sensory disorder in the knee requiring surgery
2. Coagulation abnormalities
3. Severe renal or hepatic impairment
4. Chronic opioid use

Excluded (n = 4):
Not meeting inclusion criteria (n = 2)
Declined to participate (n = 2)

Randomized

Allocated to control group (n = 16)
Allocated to bupivacaine group (n = 20)

Analysis

Analyzed (n = 16)
Excluded from analysis (n = 0)

Analyzed (n = 20)
Excluded from analysis (n = 0)

Figure 1: Flow diagram of the study.

40 patients who underwent total knee arthroplasty were assessed for eligibility (n = 40)

Exclusion criteria:
1. Sensory disorder in the knee requiring surgery
2. Coagulation abnormalities
3. Severe renal or hepatic impairment
4. Chronic opioid use

Excluded (n = 4):
Not meeting inclusion criteria (n = 2)
Declined to participate (n = 2)

Randomized

Allocated to control group (n = 16)
Allocated to bupivacaine group (n = 20)

Analysis

Analyzed (n = 16)
Excluded from analysis (n = 0)

Analyzed (n = 20)
Excluded from analysis (n = 0)

Figure 1: Flow diagram of the study.

to a series of adverse effects, including immunosuppression [12, 13]. Multimodal analgesia may achieve optimal analgesia in the management of postoperative pain by reducing opioid consumption and its related adverse events [14, 15]. Recent studies have also shown that multimodal analgesia can improve pain relief following total knee arthroplasty [16, 17]. In addition, our results indicated that patients receiving intra-articular bupivacaine in combination with intravenous parecoxib consumed significantly less meperidine than patients receiving intravenous parecoxib postoperatively in the first 24-hour observation period. The potential advantage of the combination therapy is that patients experience less pain even though they require lower amount of narcotics. Decreased narcotic consumption may decrease the risk of opioid-related adverse events [18–20].

Intra-articular injection of 60 mL of 0.5% bupivacaine was used in the current study. Previous studies have shown that intra-articular infusion of 0.5% bupivacaine at a rate of
Table 2: Numeric rating scale (NRS) scores in POR and ward.

<table>
<thead>
<tr>
<th></th>
<th>Control group</th>
<th>Bupivacaine group</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRS in POR</td>
<td>7.9 (6.7, 9.1)</td>
<td>4.5 (3.2, 5.8)</td>
<td>0.001</td>
</tr>
<tr>
<td>NRS 24 hours later in ward</td>
<td>7.6 (6.4, 8.7)</td>
<td>4.5 (3.6, 5.3)</td>
<td>0.0002</td>
</tr>
</tbody>
</table>

Continuous variables were described as the mean and 95% confidence interval; an independent t-test was used, and statistical significance was considered when p < 0.05. POR: postoperative room.

Table 3: Postoperative pain score during the first 24 hours.

<table>
<thead>
<tr>
<th>NRS score</th>
<th>POR</th>
<th>Time (hours)</th>
<th>4</th>
<th>8</th>
<th>12</th>
<th>16</th>
<th>20</th>
<th>24</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control group (n = 16)</td>
<td>0–3</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>5</td>
<td>7</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>4–6</td>
<td>1</td>
<td>1</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>7–10</td>
<td>13</td>
<td>12</td>
<td>8</td>
<td>5</td>
<td>6</td>
<td>6</td>
<td>10</td>
</tr>
<tr>
<td>Bupivacaine group (n = 20)</td>
<td>0–3</td>
<td>10</td>
<td>5</td>
<td>6</td>
<td>8</td>
<td>8</td>
<td>10</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>4–6</td>
<td>5</td>
<td>11</td>
<td>12</td>
<td>11</td>
<td>11</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>7–10</td>
<td>5</td>
<td>4</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>2</td>
</tr>
</tbody>
</table>

Numeric rating scale (NRS) scores were divided into 3 groups: mild (NRS score: 0–3), moderate (NRS score: 4–6), and severe (NRS score: 7–10). POR: postoperative room.

Table 4: Postoperative meperidine consumption during the first 24 hours.

<table>
<thead>
<tr>
<th>Postoperative meperidine consumption (mg/Kg)</th>
<th>Control group</th>
<th>Bupivacaine group</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.08 ± 0.80</td>
<td>2.34 ± 0.42</td>
<td></td>
<td>0.001</td>
</tr>
</tbody>
</table>

Continuous variables were described as mean ± standard deviation and an independent t-test was used; statistical significance was considered when p < 0.05.

Figure 2: Postoperative numeric rating scale (NRS) scores in the postoperative room (POR) and on the ward. Means and 95% confidence intervals are shown. Scores of the bupivacaine group were lower than those of the control group postoperatively during the first 24 hours. The numbers of patients contributed to each data point were the same as the initial numbers of patients.

2 mL/h for 48 hours produces little or no pain relief [21]. The results suggest that a relatively large bolus injection of bupivacaine may produce better pain relief than a small continuous infusion. The pain relief effect of intra-articular bupivacaine may be associated with the degree of infiltration from the site of injection to the soft tissue around the joint. However, the precise mechanism remains to be determined.

Some limitations of this study should be considered. We did not record mobilization data, and pain scores were determined only at rest. The pain rating at rest alone is not very helpful as it is the functional outcome that is of clinical interest. This includes pain during movement, quadriceps strength, and early ambulation. Evaluation of pain during movement is suggested for further study. Furthermore, a pilot study was not performed to calculate the required sample size. In this study, with such a small sample size, the investigation may not have been sufficiently convincing. In addition, a single-bolus dose of bupivacaine was used in this study. A third group with a higher or lower bupivacaine dose to determine the optimal dose/volume of bupivacaine is suggested for a future study.

5. Conclusion

In conclusion, intra-articular bupivacaine in combination with intravenous parecoxib improved pain relief and reduced the demand for rescue analgesics in patients undergoing total knee arthroplasty.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.
References


